

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Kocsis <i>et al.</i>	Confirmation No.: <i>To be assigned</i>
Application No.: 10/584,661 (National Stage Application of PCT/HU2004/000123)	Art Unit: <i>To be assigned</i>
Filed: June 26, 2006 (International Filing Date: December 18, 2004)	Examiner: <i>To be assigned</i>
For: Novel Pharmaceutical Compositions With Increased Activity	Atty. Docket: 0103-0004/2

Information Disclosure Statement

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Sir:

Listed on accompanying Form PTO-SB08B are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97, and 1.98. Copies of these documents are provided herein.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-SB08B based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that has been cited or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).


This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-SB8B, and to indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 503626.

Respectfully submitted,

RAKOCZY MOLINO MAZZOCHI SIWIK LLP



Nancy J. Leith
Agent for Applicants
Registration No. 45,309

Date: September 19, 2006

6 W. Hubbard St.
Suite 500
Chicago, Illinois 60610
(312) 225-6342

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/584,661
Filing Date	June 26, 2006(Intl FD12/18/04)
First Named Inventor	Kocsis
Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	0103-0004/2

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		LEANDER, Fluoxetine, a Selective Serotonin-Uptake Inhibitor, Enhances the Anticonvulsant Effects of Phenytoin, Carbamazepine. . . (LY201116), Epilepsia 33(3): 573-576 (1992)	
		RAJU et al., Effect of Fluoxetine on Maximal Electroshock Seizures in Mice: Acute VS Chronic Administration, Pharm. Res. 39(6): 451-454 (1999)	
		RAPEPORT et al., Absence of a Sertraline-Mediated Effect on the Pharmacodynamics of Carbamazepine, J. Clin. Psych. 57: 20-23 (1996)	
		PCT International Search Report for PCT/HU2004/000123	
		PCT Written Opinion for PCT/HU2004/000123	
		PCT International Preliminary Report on Patentability (IPER) for PCT/HU2004/000123	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.